Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation

This study compared two main different induction protocols used to treat myeloma eligible patients in Brazil. VCD against CTD.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Multiple Myeloma Blood Protein Disorders Cardiovascular Diseases Effects of Chemotherapy Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Immune System Diseases Immunoproliferative Disorders Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Neoplasms, Plasma Cell Paraproteinemias Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

About this study

The primary aim was observe response rate after 4 induction cycles.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

multiple myeloma newly diagnose elegible to autologous transplantation Patients submitted to ctd or vcd Myeloma patients newly diagnose >18yo

Exclusion criteria

other chemotherapy induction protocol

Treatment and study plan

Bortezomib, cyclophosphamide, thalidomide, dexamethasone

Drug

Comparison between two triple combination chemotherapy that include in different new drugs (bortezomibe e talidomida)

Other names: Velcade, genuxal, decadron

Primary outcomes

Response rate better than very good partial response after 4 induction cycles

Time frame: Response rate after induction phase - at the end of cycle 4- (28 days each cycle)- time frame trough study completion

The primary outcome is to observe the difference response rate between VCD and CTD induction myeloma elegible patient

Sponsors and collaborators

Lead sponsor

Grupo de Estudos Multicentricos em Onco-Hematologia

Network

Registry information

Official study title

Superiority of the Triple Combinations of Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in Patients With Newly Diagnose Multiple Myeloma, Eligible for Transplantation

Acronym: GBRAM003r

Important dates

Study start: 2009
Primary completion: 2014
Study completion: 2017
First posted: Jan 18, 2018
Registry last updated: Jan 18, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed